Ibrutinib No Longer Approved for MCL, MZL: How This Change Will Affect Patients
The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.
Lymphoma
LYMPHOMA ADVISOR
FEATURED CONTENT
-
-
ART and Pediatric Cancer: Risk May Vary by Method Used, Cancer Type
Research has suggested that ART may increase the risk of pediatric cancers, but studies have shown conflicting results, and questions remain. -
ASH 2022: MCL Trials Break New Ground, May Change Practice
Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers. -
ASH 2022: New Findings in CLL
Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients. -
ASH 2022: Trials Show Promising Results in Follicular Lymphoma
Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.
LYMPHOMA NEWS
Pirtobrutinib Produces Durable Responses in Relapsed/Refractory MCL
Childhood Cancer Survivors Have Higher Risk of Late Surgical Interventions
AYA Cancer Survivors Have Increased Risk of HPV-Linked Subsequent Cancer
Epkinly Approved for Relapsed, Refractory Diffuse Large B-Cell Lymphoma
Venetoclax and Obinutuzumab ± Ibrutinib Bests Chemoimmunotherapy in CLL
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
Loading... 
Loading...